Thomas A Hope

2 months ago | jnm.snmjournals.org | Liza Lindenberg |Thomas A Hope |Frank Lin |Steven Rowe

RESULTSOf 32 patients screened, 30 were enrolled into the study and received 68Ga-PSMA-R2. Two patients without BCR or mPC were not enrolled. In phase 1, 6 patients with BCR were enrolled; in phase 2, 24 patients with BCR or mPC (n = 12 each) were enrolled (Supplemental Table 2). All participants completed the imaging assessment on day 1. Most participants were White (90%, 27/30) with a median age of 70.5 y (range, 53–86 y) (Table 1).

Feb 8, 2024 | urotoday.com | Thomas A Hope

Read the Full Video TranscriptThomas Hope: Okay, here we go. PSMA in the initial staging setting. I think what I want to do in this talk is just compare and contrast ProPSMA, and I called it PreRP because that's our initial staging trial, but really the whole category of registrational studies that were performed in the US in the initial staging setting, and think about what are the differences and what's the value of both of them. I'm going to start off talking about ProPSMA.

Sep 25, 2023 | urotoday.com | Thomas A Hope

Read the Full Video TranscriptPhillip Koo: Hi, my name is Phillip Koo and welcome to UroToday. Today, we have with us Dr. Thomas Hope from UCSF to talk about the recently published consensus statement on patient selection and appropriate use of lutetium-177-PSMA-617 radionuclide therapy that was recently published in the Journal of Nuclear Medicine. First off, Tom, congratulations on getting this to the finish line so quickly with a very multidisciplinary group of physicians.

Sep 25, 2023 | urotoday.com | Thomas A Hope

Read the Full Video TranscriptPhillip Koo: Hi, my name is Phillip Koo and welcome to UroToday. Today, we have with us Dr. Thomas Hope from UCSF to talk about the recently published consensus statement on patient selection and appropriate use of lutetium-177-PSMA-617 radionuclide therapy that was recently published in the Journal of Nuclear Medicine. First off, Tom, congratulations on getting this to the finish line so quickly with a very multidisciplinary group of physicians.

Jun 8, 2023 | jnm.snmjournals.org | Thomas A Hope |Emmanuel S. Antonarakis |Lisa Bodei |Jérémie Calais

CURRENT CLINICAL STRUGGLESPatients should be effectively castrate for the duration of PSMA RLT. Patients may also receive treatment with ARPIs such as abiraterone or enzalutamide. In the VISION trial, 53% of patients initiated ARPIs along with 177Lu-PSMA-617, and ARPIs can be safely continued during PSMA RLT treatment (14). Currently, there is no evidence for or against using ARPI with PSMA RLT.